Literature DB >> 22191465

Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia.

Edgar Faber1, Adam Kuba, Jana Zapletalová, Martina Divoká, Šárka Rožmanová, Peter Rohoň, Milena Holzerová, Marie Jarošová, Karel Indrák.   

Abstract

We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-α) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4-212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7-40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase-polymerase chain reaction ["complete" molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4-10) years, while 2 continue with IFN-α and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01-0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-α therapy and required imatinib, patients who achieved CMR had excellent long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22191465      PMCID: PMC3354581          DOI: 10.1089/jir.2011.0108

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  15 in total

1.  Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.

Authors:  Guanchao Jiang; Fan Yang; Marilyn Li; Karen Weissbecker; Sherrie Price; K C Kim; Vincent F La Russa; Hana Safah; Melanie Ehrlich
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

2.  Clonal origin of chronic myelocytic leukemia in man.

Authors:  P J Fialkow; S M Gartler; A Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1967-10       Impact factor: 11.205

3.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.

Authors:  M Talpaz; H Kantarjian; R Kurzrock; J M Trujillo; J U Gutterman
Journal:  Ann Intern Med       Date:  1991-04-01       Impact factor: 25.391

4.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

Authors:  T Holyoake; X Jiang; C Eaves; A Eaves
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

5.  The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells.

Authors:  A Pierce; D L Smith; L V Jakobsen; A D Whetton; E Spooncer
Journal:  Hematol J       Date:  2001

Review 6.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

Authors:  J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

Review 7.  Interferon alpha and T-cell responses in chronic myeloid leukemia.

Authors:  Andreas Burchert; Andreas Neubauer
Journal:  Leuk Lymphoma       Date:  2005-02

Review 8.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis J Giles; Mary Beth Rios; Stefan H Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

10.  Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

Authors:  Anna Kreutzman; Peter Rohon; Edgar Faber; Karel Indrak; Vesa Juvonen; Veli Kairisto; Jaroslava Voglová; Marjatta Sinisalo; Emília Flochová; Jukka Vakkila; Petteri Arstila; Kimmo Porkka; Satu Mustjoki
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.